CTOs on the Move

CuraPharm Inc

www.curapharminc.com

 
CuraPharm Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.curapharminc.com
  • 11835 Carmel Mountain Rd Ste 1304
    San Diego, CA USA 92128
  • Phone: 619.449.7388

Executives

Name Title Contact Details

Similar Companies

Oncology Care Associates

Oncology Care Associates is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zealand Pharma

Changing lives with next generation peptide therapeutics

Spectrum Sciences

Spectrum Sciences is a California, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bryan LGH

Bryan LGH is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.